Conference Report

Integration of Targeted Therapy and Traditional Chemotherapy in Advanced NSCLC

Source: CCO Independent Conference Coverage of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Integration of Targeted Therapy and Traditional Chemotherapy in Advanced NSCLC

Program Director: Corey J. Langer, MD, FACP

Faculty:

Ramaswamy Govindan, MD
Giorgio V. Scagliotti, MD, PhD

CREDIT INFORMATION

Release Date: February 20, 2009

Expiration Date: February 19, 2010

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize recent data on the efficacy of adding targeted agents to standard chemotherapy regimens for the treatment of non-small-cell lung cancer
Discuss the latest results from studies comparing targeted agent monotherapy with chemotherapy alone or chemotherapy combined with targeted therapy in patients with non-small-cell lung cancer
Recount data from clinical trials investigating combinations of agents targeting different signaling pathways in non-small-cell lung cancer

Topics covered include:

Updated Analysis of AVAiL: First-line Bevacizumab Combined With Cisplatin/Gemcitabine in NSCLC
Erlotinib and Bevacizumab in Advanced NSCLC
Cetuximab Plus Bevacizumab With Carboplatin/Paclitaxel in Advanced NSCLC
Gefitinib in Clinically Selected Asian Patients With Advanced NSCLC
Sequential Erlotinib and Chemotherapy in Asian Patients With Advanced NSCLC
Use of Biomarkers to Predict Clinical Benefit With Erlotinib in NSCLC
Thymidylate Synthase and Pemetrexed Activity
Conclusion

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.